目的 觀察匹多莫德聯(lián)合氨溴特羅口服液治療小兒急性支氣管炎的臨床療效。方法 選取2015年1月-2016年1月三門峽市中心醫(yī)院收治的急性支氣管炎患兒82例，隨機(jī)分為對照組和治療組，每組各41例。對照組口服氨溴特羅口服液，未滿8個(gè)月，2.5 mL/次；8個(gè)月~1歲，5 mL/次；2~3歲，7.5 mL/次；4~5歲，10 mL/次；6~12歲，15 mL/次，均為2次/d；治療組在對照組的基礎(chǔ)上口服匹多莫德分散片，0.4 g/次，2次/d。兩組患兒均連續(xù)治療7 d。比較兩組患者臨床療效、臨床癥狀體征消失時(shí)間，對比兩組治療前后IgG、IgA、IgM指標(biāo)水平。結(jié)果 治療后，對照組和治療組的總有效率分別為92.68%和97.56%，兩組總有效率比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。與對照組相比，治療后治療組患兒咳嗽及肺部啰音消失的更快，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患兒IgG、IgM水平明顯升高，治療組患兒IgA水平比治療前明顯升高，同組治療前后差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療后治療組患兒IgG、IgA、IgM水平明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 匹多莫德聯(lián)合氨溴特羅口服液治療小兒急性支氣管炎具有良好的臨床療效，癥狀體征改善明顯，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To observe the clinical efficacy of pidotimod combined with ambroxol and clenbuterol in treatment of children with acute bronchitis. Methods Children (82 cases) with acute bronchitis in Sanmenxia Central Hospital from January 2015 to January 2016 were randomly divided into control and treatment groups, and each group had 41 cases. Patients in the control group were po administered with Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution, and children less than 8 months were given 2.5 mL/time, 5 mL/time for 8 months-1 year old children, 7.5 mL/time for 2-3 years old children, 10 mL/time for 4-5 years old children, 15 mL/time for 6-12 years old children, and all of them were given twice daily. Children in the treatment group were po administered with Pidotimod Dispersible Tablets on the basis of the control group, 0.4 g/time, twice daily. Patients in two groups were treated for 7 d. After treatment, the clinical efficacies and clinical signs and symptoms, the disappearing time of clinical signs and symptoms, IgG, IgA, and IgM in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 92.68% and 97.56%, respectively, and there were differences between two groups (P<0.05). Compared with the control group, the disappearing time of cough symptom and pulmonary rales in the treatment group after treatment were shorter than those in the control group, with significant difference between two groups (P<0.05). After treatment, IgG and IgM in two groups was significantly increased, IgA in the treatment group was significantly increased, and the difference was statistically significant in the same group (P<0.05). And these indicators in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Pidotimod combined with ambroxol and clenbuterol has a significant clinical curative effect in treatment of children with acute bronchitis, and can obviously improve the symptoms, which has a certain clinical application value.